Ratings Smith & Nephew Plc

Equities

SN.

GB0009223206

Real-time Estimate Cboe Europe Other stock markets 11:15:38 2024-04-23 am EDT			5-day change	1st Jan Change
986.7 ^GBX	+1.22%		+2.64%	-8.45%

Apr. 11	UK Stocks Retreat as Hope for June BoE Rate Cut Dissipates	MT
Apr. 11	Proxy Advisers Raise Concerns Over Smith & Nephew's Pay Hike Proposal	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation
The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Strengths

The earnings growth currently anticipated by analysts for the coming years is particularly strong.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
SMITH & NEPHEW PLC	-8.45%	10.48B		A-
STRYKER CORPORATION	+9.95%	125B		A-
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	-3.67%	8.42B		C
INSPIRE MEDICAL SYSTEMS, INC.	+11.54%	6.82B		C
GLAUKOS CORPORATION	+25.62%	4.96B		B+
AXONICS, INC.	+7.00%	3.41B		C-
ENOVIS CORPORATION	-0.09%	3.04B		B-
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-13.77%	2.1B	-	-
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-9.83%	1.97B		-
DOUBLE MEDICAL TECHNOLOGY INC.	-28.36%	1.66B	-	C-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes